content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): January 25, 2006
                                                           ----------------
  
                                 CYTOGEN CORPORATION
                 ---------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                     000-14879                 22-2322400
  ----------------------------   ------------------------      -------------------
  (State or Other Jurisdiction   (Commission File Number)       (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ             08540
  ---------------------------------------------------------       ----------------
           (Address of Principal Executive Offices)                  (Zip Code)
  
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  
  
  <PAGE>
  
  ITEM 8.01     OTHER EVENTS.
  
       On January 25, 2006, Cytogen Corporation (the "Company")  announced that it
  has filed a complaint  against  Advanced  Magnetics,  Inc. in the  Massachusetts
  Superior Court for breach of contract,  fraud, unjust enrichment,  and breach of
  the  implied  covenant  of good faith and fair  dealing in  connection  with the
  parties'  2000  license  agreement,   as  amended,   for  both  Combidex(R)  and
  ferumoxytol, formerly Code 7228.
  
       These matters were  announced in a press release  issued  January 25, 2006,
  which is attached  hereto as Exhibit 99.1.  The Complaint  with respect to these
  matters is attached hereto as Exhibit 99.2.
  
       The Company  does not intend to file  further  current  reports on Form 8-K
  describing  pleadings  with  related to this  lawsuit,  unless  material  to the
  Company.
  
  ITEM 9.01     FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibits.
  
      Exhibit No.      Description
      -----------      -----------
  
         99.1          Press Release of Cytogen Corporation dated January 25, 2006
  
         99.2          Complaint  filed January 25, 2006  in the Superior Court of
                       the Commonwealth of Massachusetts
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
  
  
                                          By: /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated:   January 25, 2006
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
      Exhibit No.      Description
      -----------      -----------
  
         99.1          Press Release of Cytogen Corporation dated January 25, 2006
  
         99.2          Complaint  filed January 25, 2006  in the Superior Court of
                       the Commonwealth of Massachusetts
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8-k_012506.txt", "description": "FORM 8-K FILED 01-25-06", "secsgml_size_bytes": 4441}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "06550433"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): January 25, 2006
                                                           ----------------
  
                                 CYTOGEN CORPORATION
                 ---------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
            Delaware                     000-14879                 22-2322400
  ----------------------------   ------------------------      -------------------
  (State or Other Jurisdiction   (Commission File Number)       (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ             08540
  ---------------------------------------------------------       ----------------
           (Address of Principal Executive Offices)                  (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  ITEM 8.01     OTHER EVENTS.
  
       On January 25, 2006, Cytogen Corporation (the "Company")  announced that it
  has filed a complaint  against  Advanced  Magnetics,  Inc. in the  Massachusetts
  Superior Court for breach of contract,  fraud, unjust enrichment,  and breach of
  the  implied  covenant  of good faith and fair  dealing in  connection  with the
  parties'  2000  license  agreement,   as  amended,   for  both  Combidex(R)  and
  ferumoxytol, formerly Code 7228.
  
       These matters were  announced in a press release  issued  January 25, 2006,
  which is attached  hereto as Exhibit 99.1.  The Complaint  with respect to these
  matters is attached hereto as Exhibit 99.2.
  
       The Company  does not intend to file  further  current  reports on Form 8-K
  describing  pleadings  with  related to this  lawsuit,  unless  material  to the
  Company.
  
  ITEM 9.01     FINANCIAL STATEMENTS AND EXHIBITS.
  
  (c) Exhibits.
  
      Exhibit No.      Description
      -----------      -----------
  
         99.1          Press Release of Cytogen Corporation dated January 25, 2006
  
         99.2          Complaint  filed January 25, 2006  in the Superior Court of
                       the Commonwealth of Massachusetts
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
                                          By: /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated:   January 25, 2006
  EXHIBIT INDEX
  
      Exhibit No.      Description
      -----------      -----------
  
         99.1          Press Release of Cytogen Corporation dated January 25, 2006
  
         99.2          Complaint  filed January 25, 2006  in the Superior Court of
                       the Commonwealth of Massachusetts